IgG4-related disease

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:284264
Who is this for?
Show terms as
1FDA treatments16Active trials48Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

IgG4-related disease (also called IgG4-RD) is an uncommon condition in which the immune system causes inflammation and scarring (fibrosis) in one or more organs of the body. The name comes from a specific type of antibody called immunoglobulin G4 (IgG4), which is often found at high levels in the blood and in affected tissues. This disease can affect almost any organ, but the most commonly involved areas include the pancreas, salivary glands, tear glands (lacrimal glands), bile ducts, kidneys, lungs, and the tissue around the aorta (the body's largest blood vessel). When the pancreas is affected, it can be mistaken for pancreatic cancer. When salivary or tear glands swell, it may look like Sjögren syndrome or lymphoma. Symptoms depend on which organs are involved. Common signs include painless swelling of glands, abdominal pain, jaundice (yellowing of the skin), kidney problems, or shortness of breath. Many patients have multiple organs affected at the same time or over the course of the disease. The condition tends to develop slowly, and patients may not notice symptoms until significant damage has occurred. IgG4-related disease is not a cancer and is not an infection. It is considered an immune-mediated condition, meaning the body's own immune system mistakenly attacks healthy tissues. Treatment typically involves medications that suppress the overactive immune response. Corticosteroids like prednisone are the first-line treatment and are very effective in most patients. For patients who relapse or cannot tolerate steroids, other immunosuppressive drugs or the targeted biologic rituximab may be used. Early diagnosis and treatment are important to prevent permanent organ damage from fibrosis.

Also known as:

Key symptoms:

Painless swelling of salivary glands in the cheeks or under the jawSwelling of tear glands causing puffy eyelidsYellowing of the skin and eyes (jaundice)Abdominal or back painUnexplained weight lossFatigue and general tirednessKidney problems or decreased kidney functionShortness of breath or coughDry eyes or dry mouthEnlarged lymph nodesThyroid gland enlargementNumbness or tingling from nerve involvementSkin rashes or nodulesDifficulty swallowingSwelling around the aorta or other blood vessels

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2026Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD

Amgen — PHASE2

TrialNOT YET RECRUITING
Jan 2026Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

Acepodia Biotech, Inc. — PHASE1, PHASE2

TrialRECRUITING
Dec 2025An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease

Changhai Hospital — EARLY_PHASE1

TrialNOT YET RECRUITING
Nov 2025A Study of Efgartigimod in Patients With IgG4-Related Disease

Stanford University — PHASE2

TrialRECRUITING
Sep 2025A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

Sanofi — PHASE3

TrialRECRUITING
Sep 2025Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Chinese PLA General Hospital — PHASE2

TrialRECRUITING
Jul 2025A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

Peking Union Medical College Hospital — PHASE2, PHASE3

TrialRECRUITING
May 2025A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD

Luo Yaping — NA

TrialRECRUITING
Mar 2025Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease

IRCCS San Raffaele

TrialACTIVE NOT RECRUITING
Nov 2024Key Mechanisms of Abnormal T Cell Activation and Differentiation in IgG4-Related Ophthalmic Disease

Peking University Third Hospital

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Uplizna

INEBILIZUMAB· Horizon Therapeutics USA, Inc.

indicated for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients

Clinical Trials

16 recruitingView all trials with filters →
Phase 33 trials
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
Phase 3
Active
PI: MD (Amgen) · Sites: Palo Alto, California; Atlanta, Georgia +70 more · Age: 1899 yrs
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Phase 3
Actively Recruiting
· Sites: San Jose, California; Tustin, California +56 more · Age: 1899 yrs
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
Phase 3
Active
· Sites: Stanford, California; Naples, Florida +63 more · Age: 1899 yrs
Phase 22 trials
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
Phase 2
Actively Recruiting
PI: JIAN ZHU, M.D./Ph.D. (Department of Rheumatology and Immunology, the Fir) · Sites: Beijing, Beijing Municipality · Age: 1875 yrs
A Study of Efgartigimod in Patients With IgG4-Related Disease
Phase 2
Actively Recruiting
PI: Matthew C Baker, MD, MS (Stanford University) · Sites: Palo Alto, California · Age: 1890 yrs
N/A4 trials
Short-term Glucocorticoid Combined with MMF for IgG4-RD
N/A
Actively Recruiting
PI: Wen Zhang, MD (Peking Union Medical College Hospital) · Sites: Beijing, Beijing Municipality · Age: 1880 yrs
A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
N/A
Actively Recruiting
PI: Yaping LUO, MD (Peking Union Medical College Hospital) · Sites: Beijing, Beijing Municipality · Age: 1875 yrs
Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement
N/A
Actively Recruiting
PI: Wen Zhang, MD (Peking Union Medical College Hospital) · Sites: Beijing · Age: 1875 yrs
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
N/A
Actively Recruiting
PI: Wen Zhang, MD (Peking Union Medical College Hospital) · Sites: Beijing · Age: 1875 yrs
Other3 trials
A Prospective Cohort Study of IgG4RD in China
Actively Recruiting
PI: Wen Zhang, MD (Deptment of Rheumatology, Peking Union Medical Col) · Sites: Beijing, Beijing Municipality · Age: 1875 yrs
Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
Active
· Sites: Milan, MI · Age: 1899 yrs
National Registry of IgG4-RD in China
Actively Recruiting
· Sites: Beijing, Beijing Municipality

Specialists

Showing 25 of 48View all specialists →
ME
Mikael Ebbo
Specialist
5 IgG4-related disease publications
AK
Arezou Khosroshahi
ATLANTA, GA
Specialist
2 IgG4-related disease publications
PC
Pascal Chanez
Specialist
3 IgG4-related disease publications
ZW
Zachary S Wallace
Specialist
3 IgG4-related disease publications
ED
Emanuel Della-Torre
Specialist
4 IgG4-related disease publications
EC
Emma L Culver
Specialist
4 IgG4-related disease publications
NS
Nicolas Schleinitz
Specialist
8 IgG4-related disease publications
JS
John H Stone
Specialist
7 IgG4-related disease publications
GK
Guy Katz
Specialist
5 IgG4-related disease publications
WZ
Wen Zhang
Specialist
5 IgG4-related disease publications
ML
Marco Lanzillotta
Specialist
4 IgG4-related disease publications
CP
Cory A Perugino
BOSTON, MA
Specialist
2 IgG4-related disease publications
YT
Yoshiya Tanaka
Specialist
2 IgG4-related disease publications
KO
Kazuichi Okazaki
Specialist
2 IgG4-related disease publications
ET
Emanuel Della Torre
Specialist
2 IgG4-related disease publications
ZL
Zhanguo Li
Specialist
PI on 7 active trials819 IgG4-related disease publications
WM
Wen Zhang, MD
Specialist
PI on 9 active trials1 IgG4-related disease publication
JM
John H Stone, MD
Specialist
PI on 2 active trials
LD
Lingli Dong
Specialist
PI on 2 active trials80 IgG4-related disease publications
YM
Yaping LUO, MD
Specialist
PI on 1 active trial
UD
Urielle Desalbres
Specialist
PI on 21 active trials1 IgG4-related disease publication
AM
Arezou Khosroshahi, MD
ATLANTA, GA
Specialist
PI on 1 active trial1 IgG4-related disease publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources
Uplizna(INEBILIZUMAB)Horizon Therapeutics USA, Inc.

Leustatin Injection

R. W. Johnson Pharmaceutical Research Institute

Leustatin Injection — Contact R. W. Johnson Pharmaceutical Research Institute

Unverified — confirm before calling
Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to IgG4-related disease.

Search all travel grants →NORD Financial Assistance ↗

Community

Open IgG4-related diseaseForum →

No community posts yet. Be the first to share your experience with IgG4-related disease.

Start the conversation →

Latest news about IgG4-related disease

Disease timeline:

New recruiting trial: Short-term Glucocorticoid Combined with MMF for IgG4-RD

A new clinical trial is recruiting patients for IgG4-related disease

New recruiting trial: A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

A new clinical trial is recruiting patients for IgG4-related disease

New recruiting trial: Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

A new clinical trial is recruiting patients for IgG4-related disease

New recruiting trial: Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

A new clinical trial is recruiting patients for IgG4-related disease

New recruiting trial: Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement

A new clinical trial is recruiting patients for IgG4-related disease

New recruiting trial: A Prospective Cohort Study of IgG4RD in China

A new clinical trial is recruiting patients for IgG4-related disease

New recruiting trial: Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

A new clinical trial is recruiting patients for IgG4-related disease

New recruiting trial: A Study of Efgartigimod in Patients With IgG4-Related Disease

A new clinical trial is recruiting patients for IgG4-related disease

New recruiting trial: Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

A new clinical trial is recruiting patients for IgG4-related disease

New recruiting trial: A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

A new clinical trial is recruiting patients for IgG4-related disease

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which of my organs are affected by IgG4-related disease, and how much damage has already occurred?,What is my treatment plan, and how long will I need to take steroids?,What are the side effects of my medications, and how can we minimize them?,How often will I need blood tests and imaging to monitor my condition?,What are the signs of a relapse that I should watch for?,Are there clinical trials or newer treatments available for my condition?,Should I see additional specialists based on which organs are involved?

Common questions about IgG4-related disease

What is IgG4-related disease?

IgG4-related disease (also called IgG4-RD) is an uncommon condition in which the immune system causes inflammation and scarring (fibrosis) in one or more organs of the body. The name comes from a specific type of antibody called immunoglobulin G4 (IgG4), which is often found at high levels in the blood and in affected tissues. This disease can affect almost any organ, but the most commonly involved areas include the pancreas, salivary glands, tear glands (lacrimal glands), bile ducts, kidneys, lungs, and the tissue around the aorta (the body's largest blood vessel). When the pancreas is affect

How is IgG4-related disease inherited?

IgG4-related disease follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does IgG4-related disease typically begin?

Typical onset of IgG4-related disease is adult. Age of onset can vary across affected individuals.

Are there clinical trials for IgG4-related disease?

Yes — 16 recruiting clinical trials are currently listed for IgG4-related disease on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat IgG4-related disease?

25 specialists and care centers treating IgG4-related disease are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for IgG4-related disease?

2 patient support programs are currently tracked on UniteRare for IgG4-related disease. See the treatments and support programs sections for copay assistance, eligibility, and contact details.